Association of serum uric acid levels with blood pressure and the incidence of hypertension in the middle-aged and elderly populations.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
aheadofprint
Résumé
This study aimed to investigate the relationship between serum uric acid (SUA) levels and hypertension in the middle-aged and elderly populations. The cross-sectional analysis included 13 349 middle-aged and elderly general health checkup examinees without cardiovascular disease. The retrospective cohort analysis included 6659 normotensive participants (mean age: 64.6 years). Participants were divided into three groups based on their SBP/DBP levels: normal (<120/<80 mmHg), high normal (120-129/<80 mmHg), and elevated (130-139/80-89 mmHg), and were classified into three groups based on the results of 75 g oral glucose tolerance test: normoglycemia, prediabetes, and diabetes. SUA levels were significantly associated with SBP and DBP in this cross-sectional study. Over a mean 6.5-year follow-up period, 2038 participants developed hypertension. According to the SUA quartiles, the incidence of hypertension increased [26.1% in quartile (Q1) (≤4.1 mg/dl), 28.6% in Q2 (4.2-4.9 mg/dl), 32.6% in Q3 (5.0-5.8 mg/dl), 34.9% in Q4 (≥5.9 mg/dl); P for trend <0.001]. In multivariable analyses, SUA levels were positively associated with hypertension incidence only in the normal BP group [Q4 vs. Q1 odds ratio (OR): 1.64, 95% confidence intervals (CIs): 1.11-2.44; Q3 vs. Q1 OR: 1.69, 95% CI: 1.19-2.42] and in the normoglycemic group (Q4 vs. Q1 OR: 1.34, 95% CI: 1.02-1.76; Q3 vs. Q1 OR: 1.36, 95% CI: 1.07-1.74). In the middle-aged and elderly populations, normotensive or normoglycemic individuals with SUA levels at least 5 mg/dl may be potential targets for SUA management to prevent hypertension.
Identifiants
pubmed: 37851003
doi: 10.1097/HJH.0000000000003597
pii: 00004872-990000000-00340
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275:457–464.
De Becker B, Borghi C, Burnier M, van de Borne P. Uric acid and hypertension: a focused review and practical recommendations. J Hypertens 2019; 37:878–883.
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26:269–275.
Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28:1234–1242.
Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739–1742.
Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis 2018; 278:226–231.
Vallée A. Association between serum uric acid and arterial stiffness in a large-aged 40-70 years old population. J Clin Hypertens (Greenwich) 2022; 24:885–897.
Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis 2018; 71:851–865.
Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. J Hypertens 2014; 32:1621–1628.
Gill D, Cameron AC, Burgess S, Li X, Doherty DJ, Karhunen V, et al. Urate, blood pressure, and cardiovascular disease: evidence from Mendelian randomization and meta-analysis of clinical trials. Hypertension 2021; 77:383–392.
Dyer AR, Liu K, Walsh M, Kiefe C, Jacobs DR Jr, Bild DE. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 1999; 13:13–21.
Gaffo AL, Jacobs DR Jr, Sijtsma F, Lewis CE, Mikuls TR, Saag KG. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis 2013; 72:1321–1327.
Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006; 48:1031–1036.
Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49:298–303.
Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takishita S. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27:835–841.
Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the Atherosclerosis Risk in Communities Study. Hypertension 2006; 48:1037–1042.
Bombelli M, Ronchi I, Volpe M, Facchetti R, Carugo S, Dell’oro R, et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. J Hypertens 2014; 32:1237–1244.
Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18:287–292.
Lu Z, Dong B, Wu H, Chen T, Zhang Y, Wu J, et al. Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. J Hum Hypertens 2009; 23:113–121.
Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63:102–110.
Borghi C, Piani F. Uric acid and risk of cardiovascular disease: a question of start and finish. Hypertension 2021; 78:1219–1221.
Sasaki N, Ozono R, Maeda R, Higashi Y. Risk of hypertension in middle-aged and elderly participants with newly diagnosed type 2 diabetes and prediabetes. BMJ Open Diabetes Res Care 2020; 8:e001500.
Sasaki N, Maeda R, Ozono R, Nakano Y, Higashi Y. Common carotid artery flow parameters predict the incidence of hypertension. Hypertension 2021; 78:1711–1718.
Sasaki N, Ozono R, Higashi Y, Maeda R, Kihara Y. Association of insulin resistance, plasma glucose level, and serum insulin level with hypertension in a population with different stages of impaired glucose metabolism. J Am Heart Assoc 2020; 9:e015546.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 2019; 42:1235–1481.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 2023; 46: (Suppl 1): S19–S40.
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Diagnostic criteria for dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb 2013; 20:655–660.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Summary of Recommendation Statements. Kidney Inter Suppl 2013; 3:5–14.
Ramsdell CM, Kelley WN. The clinical significance of hypouricemia. Ann Intern Med 1973; 78:239–242.
Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One 2013; 8:e56546.
Kansui Y, Ohtsubo T, Goto K, Sakata S, Ichishima K, Fukuhara M, et al. Association of serum uric acid with blood pressure in Japanese men. Cross-sectional study in work-site group. Circ J 2011; 75:2827–2832.
Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens 2007; 25:1583–1589.
King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich) 2004; 6:562–568.
Kim M, Yoo HJ, Kim M, Ahn HY, Park J, Lee SH, et al. Associations among oxidative stress, Lp-PLA2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension. Atherosclerosis 2017; 257:179–185.
Cuspidi C, Sala C, Tadic M, Gherbesi E, Grassi G, Mancia G. Prehypertension and subclinical carotid damage: a meta-analysis. J Hum Hypertens 2019; 33:34–40.
Wasserman DH, Wang TJ, Brown NJ. The vasculature in prediabetes. Circ Res 2018; 122:1135–1150.
Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension 2018; 71:78–86.
Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15:189–192.
Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421–426.
Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, et al. from the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension 2020; 75:302–308.
Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, et al. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail 2020; 22:2093–2101.
Tseng WC, Chen YT, Lin YP, Ou SM, Yang CY, Lin CH, Tarng DC. Taiwan Geriatric Kidney Disease (TGKD) Research Group Hyperuricemia predicts an early decline in renal function among older people: a community-based cohort study. Sci Rep 2019; 9:980.
Borghi C, Agnoletti D, Cicero AFG, Lurbe E, Virdis A. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. Hypertension 2022; 79:1927–1936.
Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multiethnic study of atherosclerosis. Hypertension 2011; 57:1101–1107.
Amagai Y, Ishikawa S, Gotoh T, Kayaba K, Nakamura Y, Kajii E. Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study. J Epidemiol 2006; 16:161–166.
Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18:858–865.